European Union - English - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicin hydrochloride - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastic agents - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

European Union - English - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

city medical store - sole proprietorship l.l.c germany - 1 single use glass vial - injection - 100mg / vial - malignant disease,immunosuppresion-cytotoxics

Israel - English - Ministry of Health

megapharm ltd - bleomycin sulfate - powder for solution for injection - bleomycin sulfate 15000 iu/vial - bleomycin - bleomycin - bleomycin is useful in the management of the following neoplasms: squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. well differentiated tumors usually respond better than anaplastic ones.hodgkin's disease and other malignant lymphomas, including mycosis fungoides. testicular carcinoma (seminoma and no seminoma) .malignant effusions of serous cavities (intrapleural and intraperitoneal).secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. local treatment of refractory warts. bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Israel - English - Ministry of Health

taro international ltd, israel - anastrozole - film coated tablets - anastrozole 1.0 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Singapore - English - HSA (Health Sciences Authority)

specialised therapeutics asia pte ltd - trabectedin - injection, powder, for solution - 1.0mg/vial - trabectedin 1.0mg/vial

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mundipharma pharmaceuticals sdn. bhd. - pralatrexate -

Israel - English - Ministry of Health

megapharm ltd - ifosfamide - powder for solution for inj/inf - ifosfamide 1 g/vial - ifosfamide - testicular tumourfor combination chemotherapy in patients with advanced stage ii to iv tumours according to the tnm classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy.cervical cancerpalliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, figo stage iv b (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy.breast cancerfor palliative therapy in advanced, therapy-refractory or recurrent breast cancer.non-small-cell lung cancerfor mono- or combination chemotherapy of patients with inoperable or metastatic tumours.small-cell lung cancerfor combination chemotherapy.soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma)for mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. for mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy.ewing’s sarcomafor combination chemotherapy after failure of primary cytostatic therapy.non-hodgkin’s lymphomafor combination chemotherapy in patients with highly malignant non-hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. for combination therapy of patients with recurrent tumours.hodgkin’s lymphomafor the treatment of patients with primary progressive forms and early relapse of hodgkin’s lymphoma (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radio-chemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the mine protocol.

Israel - English - Ministry of Health

megapharm ltd - ifosfamide - powder for solution for inj/inf - ifosfamide 2 g/vial - ifosfamide - testicular tumourfor combination chemotherapy in patients with advanced stage ii to iv tumours according to the tnm classification (seminomas and non-seminomas), which do not respond or adequately respond to initial chemotherapy.cervical cancerpalliative cisplatin/ifosfamide combination chemotherapy (without any other combination partners) of cervical carcinoma, figo stage iv b (when curative therapy of the disease is not possible with surgery or radiotherapy) – as an alternative to palliative radiotherapy.breast cancerfor palliative therapy in advanced, therapy-refractory or recurrent breast cancer.non-small-cell lung cancerfor mono- or combination chemotherapy of patients with inoperable or metastatic tumours.small-cell lung cancerfor combination chemotherapy.soft-tissue sarcoma (incl. osteosarcoma and rhabdomyosarcoma)for mono- or combination chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard therapies. for mono- or combination chemotherapy of other soft-tissue sarcomas after failure of surgery and radiation therapy.ewing’s sarcomafor combination chemotherapy after failure of primary cytostatic therapy.non-hodgkin’s lymphomafor combination chemotherapy in patients with highly malignant non-hodgkin’s lymphoma which does not respond, or only insufficiently responds, to the initial therapy. for combination therapy of patients with recurrent tumours.hodgkin’s lymphomafor the treatment of patients with primary progressive forms and early relapse of hodgkin’s lymphoma (duration of complete remission shorter than one year) after failure of primary chemotherapeutic or radio-chemotherapeutic treatment – as part of a recognised combination chemotherapy regimen, such as the mine protocol.

Israel - English - Ministry of Health

megapharm ltd - mesna - solution for injection - mesna 400 mg/vial - mesna - prevention of urinary passage toxicity of oxazaphosphorines (ifosfamide ,cyclophosphamide, trofosamide), in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous ifosfamide, cyclophosphamide or trofosamide , urinary passage diseases in anamnesis.